Table 1.

Clinical trials of cyclooxygenase-2 (COX-2) inhibitors for the treatment of cervical neoplasia

Authors or protocol ID	Sample size	Interventions	Targeted disease	Response rate
Weppelmann and Monkemeier52	76 vs. 84 (control)	Oxyphenbutazone	Cervical cancer	5-year survival rate : 70% vs. 55% 10-year survival rate : 62% vs. 44%
Hefler et al.57	8 vs. 8 (control)	Rofecoxib	CIN* 2–3	25% vs.12.5%
Farley et al.58	12 vs. 13 (control)	Celecoxib	CIN* 2–3	75% vs. 31%
Herrera et al.59	31	Celecoxib	Cervical cancer	81%
Gaffney et al.60	84	Celecoxib	Cervical cancer	Toxicity: 48%
NCT00081263† (GOG-0207)	100	Celecoxib	CIN* 2–3	-
NCT00152828†	45	Celecoxib	Cervical cancer	-
NCT00072540† (SWOG-S0212)	100	Celecoxib	CIN* 2–3	-

^*Cervical intraepithelial neoplasia;

^†Active clinical trials (available at http://clinicaltrials.gov).